Journal of Oncology Pharmacy Practice最新文献

{"title":"Venotoclax associated hypothyroidism in a patient with acute myeloid leukemia.","authors":"Uğur Can İzlimek, Barış Karagün, Emel Gürkan","doi":"10.1177/10781552251331601","DOIUrl":"10.1177/10781552251331601","url":null,"abstract":"<p><p>IntroductionVenetoclax is a selective inhibitor of BCL2. While its combination with hypomethylating agents (HMAs) is associated with manageable side effects, thyroid dysfunction has not been previously reported.Case ReportWe present the case of a 62-year-old female with relapsed/refractory AML who was treated with azacitidine and venetoclax. Within a month, she developed hypothyroidism with elevated TSH (42.86 µIU/mL) and low FT4 (0.34 ng/dL). Baseline thyroid function tests were normal.Management & OutcomeUltrasonography showed a diffusely enlarged thyroid gland, and thyroid autoantibodies were negative, ruling out autoimmune thyroiditis.Thyroid hormone replacement therapy was initiated, normalizing thyroid function, while venetoclax was continued due to its efficacy.DiscussionThis case highlights a rare, non-autoimmune thyroid dysfunction associated with venetoclax. The absence of autoantibodies suggests a mechanism unrelated to autoimmunity, emphasizing the need for thyroid monitoring during venetoclax therapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1011-1013"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irinotecan-induced dysarthria and management.","authors":"Dennis Marjoncu, Kerri Jones","doi":"10.1177/10781552251324868","DOIUrl":"10.1177/10781552251324868","url":null,"abstract":"<p><p>BackgroundIrinotecan is chemotherapeutic agent often used in abdominal cancers such as colorectal and pancreatic cancers. While often associated with non-central nervous system (CNS) adverse effects, in rare cases it may present with paresthesias and dysarthrias. In one case, a patient received an irinotecan-containing regimen (fluorouracil, irinotecan, oxaliplatin) and experienced several neurotoxic effects, which was successfully managed.Case ReportA female patient with newly-diagnosed pancreatic cancer was started on fluorouracil, irinotecan, and oxaliplatin (modified FOLFIRINOX). She developed dysarthrias early on in the course. Causality assessment was conducted via the Naranjo criteria, yielding a score of 6, indicating a probable adverse reaction.Management & OutcomeInitially managed with steroids and lorazepam, she was eventually given a prophylactic strategy of atropine 0.4 mg and a longer infusion time of 3 h instead of 90 min with as needed lorazepam. This strategy alleviated the dysarthrias and the patient was able to complete 12 cycles of therapy, resulting in a partial response at the end of treatment.DiscussionProlonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1007-1010"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).","authors":"Kevin Thai, Jennifer Jupp, Deonne Dersch-Mills, Sunita Ghosh, Mona Shafey, Leanne Fong","doi":"10.1177/10781552241269722","DOIUrl":"10.1177/10781552241269722","url":null,"abstract":"<p><p>BackgroundDespite evidence demonstrating the effectiveness of aprepitant for chemotherapy-induced nausea and vomiting (CINV), its use in stem cell transplant settings across Canada is not standard. While pharmacokinetic data exists, the clinical significance of cytochrome P450 3A4 (CYP 3A4) inhibition of cyclophosphamide by aprepitant is unclear. Reduced activation of cyclophosphamide may reduce the effectiveness of dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).ObjectivesTo compare response rates to DICEP in patients with Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) in the presence and absence of aprepitant.MethodsA retrospective review of patients who received full-dose DICEP for relapsed/refractory HL or DLBCL between June 1995 and September 2018 at the Foothills Medical Centre (FMC) in Calgary, Alberta, Canada was conducted. Descriptive statistics were used to assess response rate, as defined by the 2007 International Working Group response criteria.ResultsOf the 218 patients included in this study, 87.6% of patients in the control group and 88.5% of patients in the aprepitant group responded to DICEP (difference 0.025 [95% CI, -0.066 to 0.114], p = 0.827). Univariate analyses for age, sex, type of cancer, stage of cancer, number of prior relapses, and relapse status were not significant. No significant differences were observed for secondary outcomes.ConclusionResponse rates to DICEP in relapsed/refractory HL and DLBCL patients were similar regardless of aprepitant use. Considering these results and the effectiveness of aprepitant in CINV, its addition to standard antiemetic therapy in patients receiving DICEP should be given strong consideration in the transplant setting.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"949-954"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncology stewardship: A narrative review of principles and practices.","authors":"Bushra Salman, Amna Mohamed, Intisar Al-Riyami, Anas Hamad, Murtadha Al-Khabori","doi":"10.1177/10781552251372492","DOIUrl":"https://doi.org/10.1177/10781552251372492","url":null,"abstract":"<p><p>IntroductionThe rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems.MethodsThis narrative review followed the conceptual synthesis approach outlined by Baumeister & Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings.ResultsFive core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation.ConclusionOS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251372492"},"PeriodicalIF":0.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing chemotherapy practices: The impact of dose banding on reissuing and waste reduction.","authors":"Alida Geertruida Catharina van Huët, Helle-Brit Fiebrich-Westra, Peder Nygård, Elise Joëlle Smolders","doi":"10.1177/10781552251370560","DOIUrl":"https://doi.org/10.1177/10781552251370560","url":null,"abstract":"<p><p>ObjectivesDose banding has been introduced to prevent waste caused by cancellation of the chemotherapeutic agents paclitaxel, carboplatin, docetaxel, gemcitabine, irinotecan and oxaliplatin. This could enhance the interchangeability of reconstituted chemotherapy, improving sustainability and cost-efficiency in healthcare. The aim of this project is to evaluate the impact of dose banding on the increase of reissuing admixtures and reduction of medication waste.MethodsDose bands were created, allowing a maximum deviation of 10% from the prescribed dose. These dose rounding rules were implemented in Hix 6.2 (ChipSoft BV). Drug waste (already prepared admixtures) and reissuing of admixtures were compared one year before and after implementation. Admixtures eligible for reissuing were identified, and reissued preparations were quantified as percentages of total eligible treatments. Economic benefits were calculated using product, material and preparation costs.ResultsPost-implementation, reissuing increased for all chemotherapies except carboplatin. The largest improvement was seen for oxaliplatin, where reissuing increased from 3.7% to 27.8%, which is an absolute increase of reissuing from 1 to 5 admixtures. Waste was reduced for all agents except carboplatin, with paclitaxel 80 mg/m² showing the greatest reduction, an absolute reduction of already prepared admixtures from 90 to 23. The amount of waste was significantly reduced, resulting in yearly cost savings of approximately €5,200.ConclusionsDose banding enhances the reissuing of chemotherapeutic agents by increasing interchangeability. Broader implementation of this straightforward procedure could further improve reissuing and reduction of waste in chemotherapy preparation.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251370560"},"PeriodicalIF":0.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposing standardized recommendations for de novo implementation of automated dispensing systems in oncology wards.","authors":"Soumaya El Baraka, Oualid Ziraoui, Zineb Lachhab, Ghita Meknassi Salime, Nihal Bhirich, Ali Cherif Chafchaouni, Omar El Hamdaoui, Younes Rahali","doi":"10.1177/10781552251371683","DOIUrl":"https://doi.org/10.1177/10781552251371683","url":null,"abstract":"<p><p>ObjectiveThis study aims to develop standardized recommendations for the implementation of Automated Dispensing Systems (ADS) in oncology wards, focusing on enhancing patient safety, operational efficiency, and the integration of these systems into hospital workflows.MethodA structured methodology was employed, combining documentary analysis of ADS practices at CHUIS, synthesis of strategies for implementation, and development of evidence-based recommendations validated by a multidisciplinary panel.ResultsThe primary outcome of this study was the development of standardized recommendations tailored for ADS implementation in oncology wards. Key findings included the importance of phased planning, targeted training (60 h), and integration with existing hospital IT systems. These recommendations emphasized initial audits, stakeholder engagement, and continuous monitoring to ensure sustainable and replicable practices. Enhanced medication management processes, including reductions in cytotoxic drug costs (9%), expiration-related losses (98.3%), and stockouts (41.1%), further demonstrated the transformative potential of ADS.DiscussionThe study underscores the critical role of tailored, evidence-based strategies in facilitating successful ADS adoption. These recommendations align with international safety standards and provide a scalable framework adaptable to diverse oncology settings. Limitations include the need for further exploration of resource adaptability and long-term impact on patient outcomes. The integration of emerging technologies, such as AI, presents opportunities for future optimization.ConclusionThis research highlights the value of standardized recommendations for ADS implementation in oncology wards. By addressing operational challenges and integrating innovative solutions, this study offers a practical model for enhancing oncology pharmacy practices globally.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251371683"},"PeriodicalIF":0.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of phytoconstituents in oncocosmetics: A systematic review on radiodermatitis management.","authors":"Anshul Upadhyay, Chitra Gupta, Pankaj Bhatt, Vandana Arora Sethi, Khushbu Gupta, Keerti Singh","doi":"10.1177/10781552251365873","DOIUrl":"https://doi.org/10.1177/10781552251365873","url":null,"abstract":"<p><p>ObjectiveThe article explores phytoconstituents as alternatives to corticosteroids for radiodermatitis, emphasizing antioxidant, antimicrobial, and anti-inflammatory properties. It summarizes recent research on phytoconstituents mitigating radiation-induced skin damage and contributing to \"oncocosmetics\" development for cancer patients undergoing radiotherapy.Data SourcesScientific literature was reviewed, including studies on radiodermatitis symptoms, phytoconstituent mechanisms, and their effectiveness in treating radiation-induced skin injuries. Search criteria included peer-reviewed articles on therapeutic applications and cosmeceutical formulations.Data SummaryRadiodermatitis affects 95% of individuals exposed to ionizing radiation during radiotherapy, presenting symptoms like erythema, pruritus, ulcers, and necrosis. Current treatments rely heavily on corticosteroids, which cause side effects like skin atrophy and systemic reactions. Phytoconstituents offer safer alternatives by neutralizing free radicals and protecting against radiation-induced skin damage. Their antioxidant, antimicrobial, and anti-inflammatory actions align with mechanisms involved in radiodermatitis healing. Research highlights their efficacy in preventing bacterial superinfection and promoting skin recovery. Phytoconstituents are increasingly incorporated into cosmeceutical products for cancer patients.ConclusionsPhytoconstituent-based preparations promise safer alternatives to corticosteroids for managing radiodermatitis. Their use in oncocosmetics can reduce side effects while improving patient outcomes. Further research into phytoconstituent formulations is needed for radiation-induced skin injuries.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251365873"},"PeriodicalIF":0.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of alisertib in the treatment of solid and hematological cancers: A systematic review and meta-analysis of randomized controlled trials.","authors":"Zaher Mutaz Ashour, Aws Khalid Abushanab, Osama Wadah Rammaha, Mus'ab Theeb Mustafa, Ghayda' Osama Elhaj, Aya Ahmad Al-Marahleh, Tasneem Aloqaili, Ahmad Sami Othman, Nour Maher Mustafa, Yihea Mohammad Al-Mashaqbah","doi":"10.1177/10781552251371290","DOIUrl":"https://doi.org/10.1177/10781552251371290","url":null,"abstract":"<p><p>BackgroundAlisertib, an Aurora kinase A inhibitor, has been investigated as a potential treatment for various hematologic and solid tumors. While clinical trials have suggested its efficacy in both cancer types, concerns persist regarding its safety profile particularly its hematologic and gastrointestinal toxicities. This systematic review and meta-analysis evaluate the safety of alisertib in patients with hematologic cancers and solid tumors across randomized controlled trials.MethodsOnline databases were searched comprehensively for phase II and phase III randomized controlled trials (RCTs), including the use of alisertib compared with chemotherapy in the treatment of solid and hematological tumors. The primary outcomes assessed were all-grade treatment-related adverse events (TRAEs) and grade ≥3 TRAEs, while individual adverse events (AEs) were evaluated as secondary outcomes.ResultsA pooled analysis of four studies involving 765 patients showed significantly higher rates of all-grade and grade ≥3 AEs in the alisertib group compared to chemotherapy. Hematologic toxicities, including anemia, febrile neutropenia, neutropenia, and leukopenia, were markedly increased with alisertib. Similarly, gastrointestinal AEs, particularly diarrhea, were more frequent in the alisertib group.ConclusionAlisertib significantly increases the risk of hematologic and gastrointestinal toxicities compared to chemotherapy, highlighting the need for careful monitoring and a thorough benefit-risk assessment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251371290"},"PeriodicalIF":0.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an oncohematologic pharmaceutical care model on patient experience: An observational study based on PREMs.","authors":"Dolores Rosique-Robles, Alejandro Valcuende-Rosique, Joaquín Borrás-Blasco","doi":"10.1177/10781552251371630","DOIUrl":"https://doi.org/10.1177/10781552251371630","url":null,"abstract":"<p><p>IntroductionHealthcare quality is increasingly assessed through patient-centered metrics, with Patient-Reported Experience Measures (PREMs) emerging as essential tools to evaluate the effectiveness of care models beyond clinical outcomes. In oncohematology, where treatments are prolonged and emotionally demanding, patient experience plays a critical role in therapeutic adherence and perceived safety.MethodsThis cross-sectional study was conducted at Sagunto University Hospital and included 90 patients undergoing active oncohematologic treatment. The impact of the Oncohematologic Pharmaceutical Care (OH-PC) consultation-a differentiated model integrating clinical pharmacists into direct patient care-was evaluated using a 16-item Likert survey based on validated instruments aligned with IEXPAC domains.ResultsThe OH-PC model showed significant improvements compared to the traditional medication dispensing approach. Patients reported enhanced accessibility, better quality of information, and stronger professional-patient relationships. Notably, 100% of respondents stated they received clear explanations about their treatment, and over 94% expressed high satisfaction. The model positively impacted all IEXPAC domains: productive interactions (98.2%), self-management (95.1%), and relational model (90.0%).ConclusionsThe OH-PC consultation significantly improved patient-reported experience in oncohematologic care. These findings highlight the pivotal role of pharmacists in enhancing patient-centered care and suggest that the OH-PC model could be scalable to other chronic and complex care settings. The integration of PREMs is recommended for continuous quality improvement and healthcare system transformation.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251371630"},"PeriodicalIF":0.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming language barriers to enhance pharmaceutical care: Design and validation of a pictogram-based tool for cancer patients.","authors":"Justine Clarenne, Marion Barrois, Audrey Durand, Léa Aubert, Claire Carlier, Kamelia Smati, Olivier Bouché, Florian Slimano","doi":"10.1177/10781552251369421","DOIUrl":"https://doi.org/10.1177/10781552251369421","url":null,"abstract":"<p><p>PurposeOncology Pharmacists providing care for cancer patients need access to medication history, act to prevent drug- / herb-drug interaction (HDI), educate patients on detection and management of adverse effects (AE) through proper use of supportive care. However, language barriers are common in case with less spoken languages, making communication challenging. We aimed to design and validate a set of illustrations addressing these key topics.MethodsThe design of the pictures was led by three pharmacists, focusing on three topics: general information (medication history), problems detection (AE of anticancer treatments, HDI) and the proper use of supportive care (e.g., mouthwash). Illustrations were created using Canva^® (Canva Pty Ltd, Perth, Australia). Each card underwent a two-step validation process: an on-site evaluation (Wooclap^® (Bruxelles, Belgium) for agreement/disagreement with recommendations), followed by a broader validation involving a multidisciplinary panel including oncologists, general practitioners, nurses, pharmacists, and patients- using a 9-point Likert scale on a Google^® Form (Google, Mountain View, CA, USA).ResultsA total of 53 cards were initially evaluated by 19 pharmacists who fully approved 18 of them and provided recommendations for the others. Subsequently, a panel of 27 respondents rated the 53 cards. After the first round, the mean score was 7.37 ± 1.2, with all but five cards receiving a score >6 and being validated. The clarity of four cards (weight variation, HDI, dry skin, neuropathy) was improved while one (St John's wort) was ultimately removed. The four revised cards were then resubmitted and received approval.ConclusionsA final set of 52 validated cards will help enhance pharmaceutical care for cancer patients facing language barriers.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251369421"},"PeriodicalIF":0.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}